Articles
For the first time, a therapy for non-small cell lung cancer (NSCLC) has achieved more responses in smokers than nonsmokers. The antibody MPDL3280A also achieved good responses in the squamous and adenoma histologic types of NSCLC. Read More ›
In the ongoing phase 3 PROFILE 1007 study of patients with previously treated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer, crizotinib improved quality of life (QOL) and key lung cancer symptoms compared with chemotherapy. Read More ›
Recent surveys of oncologists and hematologists show that drug shortages persist, that practitioners are adapting in ways that often raise the cost of cancer care, and that most have no guidance to aid in decision making in the face of these shortages. Read More ›
A novel ALK/EGFR (anaplastic lymphoma kinase/epidermal growth factor receptor) inhibitor—AP26113 (ARIAD Pharmaceuticals, Inc.)—achieved good responses in crizotinib-resistant and crizotinib-naive patients with non-small cell lung cancer (NSCLC) as well as radiographic regression of central nervous system (CNS) metastases in these patients. Read More ›
MedImpact Healthcare Systems, Inc. and Onco360 today announced a joint collaboration focused on offering MedImpact clients a unique and effective solution for bending the cost curve and delivering quality and value-based Oncology pharmaceutical care. Read More ›
Efficacy outcomes in acute myeloid leukemia (AML) are poorer with advanced age and the presence of FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). Read More ›
Building Bridges to Conquer Cancer, the theme of the 2013 annual American Society of Clinical Oncology (ASCO) meeting held in Chicago, IL, is an appropriate goal of all healthcare practitioners who specialize in hematology/oncology, including postgraduate year 2 (PGY-2) oncology pharmacy residents. Read More ›
Building Bridges to Conquer Cancer, the theme of the 2013 annual American Society of Clinical Oncology (ASCO) meeting held in Chicago, IL, is an appropriate goal of all healthcare practitioners who specialize in hematology/oncology, including postgraduate year 2 (PGY-2) oncology pharmacy residents. Read More ›
Efficacy outcomes in acute myeloid leukemia (AML) are poorer with advanced age and the presence of FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). Read More ›
We all go to our local pharmacy to get prescriptions filled for ourselves or a loved one. We usually notice, primarily based on the copayment, whether the prescription drug we are getting is a trade name we may see in a television commercial or it is a generic drug. Read More ›